Clinical Trial Update: NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab plus ipilimumab with temozolomide in microsatellite-stable, MGMT-silenced metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Temozolomide (Temozolomide)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED